Amgen | A Worldwide Pioneer in Biotechnology

Popular pages

• Amgen | A Worldwide Pioneer in Biotechnology

  Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics.

• Finding Balance: As we celebrate Mother’s Day, several female leaders share how Amgen fosters an

  Amgen recognizes one of the most important roles outside of the workplace. Happy Mother’s Day.

• AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE

  Amgen (NASDAQ:AMGN) and TScan Therapeutics, Inc. (NASDAQ:TCRX), today announced a multi-year collaboration that will use TScan's proprietary target discovery platform, TargetScan, to identify the ant...

• NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC

  traindications Prolia® is contraindicated in patients with hypocalcemia. Pre–existing hypocalcemia must be corrected prior to initiating Prolia®. Prolia® is contraindicated in womenÂ...

• Taking on Vasculitis, Together: Meet Rodney and Debbie | Amgen

  To gain a deeper understanding of their journey with ANCA-associated vasculitis (AAV), Amgen recently sat down with Rodney and Debbie to hear their story and what advice they have for others.

• AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022| Amgen

  AMG 133 is a First-in-Class Investigational Bispecific Molecule That Activates GLP-1R and Inhibits GIPR Phase 1 Results Showed up to 14.5% Reduction in Body Weight at the Highest Dose After 12 Weeks ...